A lab-made peptide known in research as LY3437943, developed by Eli Lilly and now in Phase 3 human trials
Early data showed potentially better body composition outcomes, though more research is needed
mechanism unexplained Relative contributions of direct peptide effects versus downstream IGF-1 actions inadequately characterized Long-term receptor sensitivity and potential for desensitization inadequately studied Individual patient variability in response not well-characterized Potential for differential effects based on endogenous growth hormone status unclear Long-Term Safety Considerations Critical safety questions remain unanswered regarding chronic peptide administration: Cardiovascular safety concerns FDA warnings cite risks of increased heart rate, systemic vasodilation, flushing, and transient hypotension Immunogenicity risks FDA identifies both peptides as potentially immunogenic with risk of serious immune reactions including anaphylaxis Cancer risk theoretical concern that chronic growth hormone/IGF-1 elevation could promote cellular proliferation
Goto T et al
Targeting heat shock proteins in cancer Targeting HSP27 Targeting HSP27 has shown promise through agents such as RP101 (bromovinyldeoxyuridine), a nucleoside antiviral compound that binds HSP27 and disrupts its interaction with client proteins
The Zr released from Mn-MOF downregulated GSH efficiently (Figure 5G), thus elevating Mn-MOF-induced ROS concentration, leading to the deactivation of GPX4 and ROS-enhanced ferroptosis
